Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum

Inclusion Criteria

- INCLUSION CRITERIA:

1. Patients with sarcomas, melanomas, germ cell tumors, or epithelial malignancies
metastatic to the lungs, mediastinum, or pleura that have no clinical evidence
of active disease (NED).

2. Patients with active disease outside the thorax may be eligible for study once
the extrathoracic disease is definitively treated by local modalities such as
radiation, surgery, or radiofrequency ablation.

3. Patients must have received or refused first line standard systemic therapy for
their metastases (if applicable).

4. Patients must be enrolled within 52 weeks following completion of metastasectomy
and have shown no evidence of disease during that time.

5. Patients with intracranial metastases, which have been treated by surgery or
radiation therapy may be eligible for study provided there is no evidence of
active disease and no requirement for anticonvulsant therapy or steroids
following treatment.

6. Patients must have an ECOG performance status of 0 - 2.

7. Patients must be 18 years of age or older due to the unknown effects of
immunologic responses to germ cell-restricted gene products during childhood and
adolescent development.

8. Patients must have evidence of adequate bone marrow reserve, hepatic and renal
function as evidenced by the following laboratory parameters:

- Absolute neutrophil count greater than 1500/mm(3)

- Platelet count greater than 100,000/mm(3)

- Hemoglobin greater than 8g/dl (patients may receive transfusions to meet
this parameter)

- PT within 2 seconds of the ULN

- Total bilirubin < 1.5 times upper limits of normal

- Serum creatinine less than or equal to 1.6 mg/ml or the creatinine
clearance must be greater than 70 ml/min/1.73m(2).

9. Seronegative for HIV antibody. Note: The experimental treatment being evaluated
in this protocol depends on an intact immune system. Patients who are HIV
seropositive can have decreased immune competence and thus may be less
responsive to the experimental treatment.

10. Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.
If hepatitis C antibody test is positive, then patient must be tested for the
presence of antigen by RT-PCR and be HCV RNA negative.

11. Patients must be aware of the neoplastic nature of their illnesses, the
experimental nature of the therapy, alternative treatments, potential benefits,
and risks.

12. Patients must be willing to practice birth control during and for four months
following treatment.

13. Patients must be willing to sign an informed consent.

EXCLUSION CRITERIA:

1. Patients who are initially rendered NED by surgical therapy but exhibit disease
progression prior to initiation of vaccination will be excluded from the study.

2. Patients requiring corticosteroids (other than inhaled) will be excluded.

3. Patients with life expectancy less than 12 months will be excluded.

4. Patients receiving warfarin anticoagulation, who cannot be transferred to other
agents such as enoxaparin or dabigatran, and for whom anticoagulants cannot be held
for up to 24 hours will be excluded.

5. Patients with uncontrolled hypertension (> 160/95), unstable coronary disease
evidenced by uncontrolled arrhythmias, unstable angina, decompensated CHF (> NYHA
Class II), or myocardial infarction within 6 months of study will be excluded.

6. Patients with other cardiac diseases may be excluded at the discretion of the PI
following consultation with Cardiology consultants.

7. Patients with any of the following pulmonary function abnormalities will be excluded:
FEV, < 30% predicted; DLCO < 30% predicted (postbronchodilator); Oxygen Saturation
less than 90% on room air.

8. Pregnant and/or lactating women will be excluded due to the unknown, potentially
harmful effects of immune response to CT-X antigens and stem cell proteins that may
be expressed in placenta, fetus, and neonates.

9. Patients with active infections, including HIV, will be excluded, due to unknown
effects of the vaccine on lymphoid precursors.